Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Y J Shimada"'
Publikováno v:
European Heart Journal. 43
Background While hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease affecting 1 in 200–500 people, it is a heterogeneous disease. Only a subset of patients with HCM develop heart failure (HF; prevalence 35–50%). P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad8331204ce5d645f02e3b60b3a23932
https://doi.org/10.1093/eurheartj/ehac544.1723
https://doi.org/10.1093/eurheartj/ehac544.1723
Autor:
N Harano, L W Liang, K Hasegawa, M S Maurer, A Tower-Rader, M A Fifer, M P Reilly, Y J Shimada
Publikováno v:
European Heart Journal. 43
Background Hypertrophic cardiomyopathy (HCM) is one of the most common genetic cardiac disorders and affects 1 in 200–500 individuals. HCM is known to be heterogeneous. Approximately 20–30% of patients with HCM develop atrial fibrillation (AF), w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bce3bcf366711d92f2d44d00aaa56d1
https://doi.org/10.1093/eurheartj/ehac544.1727
https://doi.org/10.1093/eurheartj/ehac544.1727
Publikováno v:
European Heart Journal. 43
Background Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy affecting 1 in 200–500 people in the US. It is characterized by a diverse clinical course, and only a subset of patients with HCM experience major adverse cardio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2464603a5d71f7eec37d2c67a679306
https://doi.org/10.1093/eurheartj/ehac544.1724
https://doi.org/10.1093/eurheartj/ehac544.1724
Publikováno v:
European Heart Journal. 42
Background Hypertrophic cardiomyopathy (HCM) is a heterogeneous disease, and a subset (10–15%) of patients per year experience major adverse cardiovascular events (MACE). Current risk prediction models based solely on clinical data have yielded lim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cc1490feff3983f8d86d2c7895bde21
https://doi.org/10.1093/eurheartj/ehab724.1765
https://doi.org/10.1093/eurheartj/ehab724.1765
Publikováno v:
European Heart Journal. 42
Introduction Late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (CMR) represents myocardial fibrosis. In patients with hypertrophic cardiomyopathy (HCM), LGE on CMR has been associated with an increased risk of sudden cardiac dea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eecb22a0f1a3d8ab511d35bb77d21d6d
https://doi.org/10.1093/eurheartj/ehab724.1764
https://doi.org/10.1093/eurheartj/ehab724.1764
Publikováno v:
European Heart Journal. 42
Background Hypertrophic cardiomyopathy (HCM) is caused by mutations in the genes coding for proteins essential in normal myocardial contraction. However, it remains unclear through which molecular pathways gene mutations mediate the development and p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6f4c8313545ff8a09207573b6aa6d8d
https://doi.org/10.1093/eurheartj/ehab724.1777
https://doi.org/10.1093/eurheartj/ehab724.1777